Evofem Biosciences Achieves Key Milestone for PHEXX in the UAE
Women’s health innovator Evofem Biosciences, Inc. is on the verge of a significant entry into the United Arab Emirates (UAE) market with its groundbreaking product, PHEXX®.
What is PHEXX®?
PHEXX® is a unique, hormone-free contraceptive vaginal gel, combining lactic acid, citric acid, and potassium bitartrate. This locally-acting contraceptive helps to maintain a normal vaginal microbiome while being a safe alternative to traditional hormonal methods.
A Step Toward Regulatory Approval
The Emirates Drug Establishment (EDE) recently issued favorable pricing certificates for PHEXX®. This certification plays an essential role in the journey towards obtaining regulatory approval in the UAE. Such an approval will allow Evofem to offer its innovative product to Emirati women, allowing them access to much-needed contraceptive choices.
Importance of Pricing Certification
As per Saundra Pelletier, CEO of Evofem, the pricing certification marks an important step in the company's strategy to diversify its revenue. It supports their goal to enter new markets progressively.
The Role of Pharma 1
Evofem’s licensed partner, Pharma 1, is tasked with launching PHEXX® in the UAE in 2026, subject to acquiring the necessary EDE marketing approval and fulfilling commercial prerequisites. Pharma 1 not only holds exclusive rights to PHEXX® but also to SOLOSEC®, another FDA-approved product, expanding their footprint across the Gulf Cooperation Council (GCC).
Future Opportunities and Market Expansion
The commercial rights for both PHEXX® and SOLOSEC® allow for potential growth into other regions. The anticipated demand for hormone-free contraceptives in the MENA region positions Evofem and Pharma 1 as innovators in women’s health solutions.
Pharma 1’s Commitment to Health Solutions
Since its establishment, Pharma 1 has demonstrated a steadfast commitment to addressing healthcare needs. Their focus on delivering practical and scientifically-backed solutions reflects their dedication to improving community health across the GCC.
About Evofem Biosciences
Evofem Biosciences, Inc. is at the forefront of women's healthcare, striving to meet unmet needs in sexual and reproductive health. Their FDA-approved products, including PHEXX®, are exemplary of their innovation and commitment to women's health.
Solidifying a Healthier Future
Both Evofem and Pharma 1 share a vision of supporting women's health initiatives and advancing contraceptive choices. As they work to establish PHEXX® in the UAE and potentially other regions, they will empower women and healthcare providers with the tools to make informed choices.
Frequently Asked Questions
What is PHEXX®?
PHEXX® is a hormone-free contraceptive gel that offers a local approach to contraception for women.
When is PHEXX® expected to launch in the UAE?
The anticipated launch for PHEXX® in the UAE is set for 2026, pending necessary approvals.
Who is responsible for marketing and distributing PHEXX®?
Pharma 1 handles all marketing and distribution aspects for PHEXX® in the licensed territory.
What role does Evofem play in this venture?
Evofem is the innovator of PHEXX® and has partnered with Pharma 1 for its commercial journey in the UAE.
What other products do Evofem Biosciences offer?
In addition to PHEXX®, Evofem also offers SOLOSEC®, an FDA-approved treatment for bacterial vaginosis.
